Cargando…

Optimisation of decrementing evoked potential mapping for functional substrate identification in ischaemic ventricular tachycardia ablation

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Decrement evoked potential (DeEP) mapping has been shown to identify the functional substrate critical to the Ventricular Tachycardia (VT) circuit with a higher specificity than late potential mapping.[1] However, there is limited...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Sheikhli, J, Winter, J, Patchett, I, Lim, V G, Marshall, L, Orini, M, Williams, S, Osman, F, Lellouche, N, Roca Luque, I, Lambiase, P, Porta-Sanchez, A, Dhanjal, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207243/
http://dx.doi.org/10.1093/europace/euad122.313
_version_ 1785046409030926336
author Al-Sheikhli, J
Winter, J
Patchett, I
Lim, V G
Marshall, L
Orini, M
Williams, S
Osman, F
Lellouche, N
Roca Luque, I
Lambiase, P
Porta-Sanchez, A
Dhanjal, T
author_facet Al-Sheikhli, J
Winter, J
Patchett, I
Lim, V G
Marshall, L
Orini, M
Williams, S
Osman, F
Lellouche, N
Roca Luque, I
Lambiase, P
Porta-Sanchez, A
Dhanjal, T
author_sort Al-Sheikhli, J
collection PubMed
description FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Decrement evoked potential (DeEP) mapping has been shown to identify the functional substrate critical to the Ventricular Tachycardia (VT) circuit with a higher specificity than late potential mapping.[1] However, there is limited data on methodological optimisation of this technique which could identify more relevant regions of conduction delay and functional block that occurs during clinical VT by activating the substrate at coupling intervals closer to the VT cycle length (CL). PURPOSE: The goal of this study was to investigate a range of short coupled extra-stimuli and decrement thresholds to improve DeEP mapping target identification in patients with ischaemic cardiomyopathy. METHODS: Thirteen patients (70±12 years) underwent VT ablation. Mapping was performed with the Advisor HD Grid multipolar catheter. Maps were generated using omnipolar electrograms (EGMs). DeEP mapping was performed using 3 different extra-stimuli (S2) sequentially in each case: (1) 400 ms (DeEP-400); (2) VT cycle length (VTCL); (3) ventricular effective refractory period (VERP) + 20 ms. For each of the DeEP-400, DeEP-VTCL and DeEP-VERP maps, the definition of a DeEP was altered from the standard 10 ms decrement to multiple thresholds of 10 ms to 50 ms in 10 ms increments (figure 1). DeEP maps were compared to the VT exit site identified with VT activation maps. All patients underwent DeEP-400 focused ablation. RESULTS: All patients had 1 clinical VT (VTCL = 353 ± 48 ms; VERP + 20 ms = 300 ± 20 ms). Mean left ventricular ejection fraction was 30 ± 12 %. Sensitivity and specificity analyses (figure 2) show the optimal threshold for defining a DeEP is with an EGM prolongation of ≥ 20 ms for the DeEP-400 (sens. 77%, spec. 79%, ROC AUC 0.84), DeEP-VTCL (sens. 77%, spec. 79%, ROC AUC 0.83) and DeEP-VERP (sens. 69%, spec. 74%, ROC AUC 0.76) maps. Proportional to total mapped area, the DeEP-400 map area was significantly smaller than DeEP-VERP map area (19.0 ± 7.6 % vs 26.4 ± 14.3%; p=0.02). Delivering the S2 at the conventional VERP + 20 ms using a 10 ms decrement definition yielded a sensitivity of 84.6% and a specificity of 62.0% with a target ablation area of 33.9 cm2. With the optimised protocol of delivering the S2 at 400 ms using a 20 ms decrement definition, the sensitivity remains high at 76.9% with an improved specificity of 79.0%, thus reducing the ablation target area by 50% to 16.8 cm2. 92% patients were free of any VT after DeEP-400 guided ablation at 6-month median follow-up. CONCLUSION: In this prospective, mechanistic study utilising omnipolar technology to explore a range of S2 extra-stimuli and decrement thresholds, DeEPs were optimally defined by a conduction delay of ≥ 20 ms with an S2 extra-stimulus coupling interval of 400 ms or VTCL to more accurately localise the VT exit site. This optimised DeEP mapping protocol further refines identification of the critical myocardial sites involved in the initiation and maintenance of VT. [Figure: see text] [Figure: see text]
format Online
Article
Text
id pubmed-10207243
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102072432023-05-25 Optimisation of decrementing evoked potential mapping for functional substrate identification in ischaemic ventricular tachycardia ablation Al-Sheikhli, J Winter, J Patchett, I Lim, V G Marshall, L Orini, M Williams, S Osman, F Lellouche, N Roca Luque, I Lambiase, P Porta-Sanchez, A Dhanjal, T Europace 13.4.3 - Ablation of Ventricular Arrhythmias FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Decrement evoked potential (DeEP) mapping has been shown to identify the functional substrate critical to the Ventricular Tachycardia (VT) circuit with a higher specificity than late potential mapping.[1] However, there is limited data on methodological optimisation of this technique which could identify more relevant regions of conduction delay and functional block that occurs during clinical VT by activating the substrate at coupling intervals closer to the VT cycle length (CL). PURPOSE: The goal of this study was to investigate a range of short coupled extra-stimuli and decrement thresholds to improve DeEP mapping target identification in patients with ischaemic cardiomyopathy. METHODS: Thirteen patients (70±12 years) underwent VT ablation. Mapping was performed with the Advisor HD Grid multipolar catheter. Maps were generated using omnipolar electrograms (EGMs). DeEP mapping was performed using 3 different extra-stimuli (S2) sequentially in each case: (1) 400 ms (DeEP-400); (2) VT cycle length (VTCL); (3) ventricular effective refractory period (VERP) + 20 ms. For each of the DeEP-400, DeEP-VTCL and DeEP-VERP maps, the definition of a DeEP was altered from the standard 10 ms decrement to multiple thresholds of 10 ms to 50 ms in 10 ms increments (figure 1). DeEP maps were compared to the VT exit site identified with VT activation maps. All patients underwent DeEP-400 focused ablation. RESULTS: All patients had 1 clinical VT (VTCL = 353 ± 48 ms; VERP + 20 ms = 300 ± 20 ms). Mean left ventricular ejection fraction was 30 ± 12 %. Sensitivity and specificity analyses (figure 2) show the optimal threshold for defining a DeEP is with an EGM prolongation of ≥ 20 ms for the DeEP-400 (sens. 77%, spec. 79%, ROC AUC 0.84), DeEP-VTCL (sens. 77%, spec. 79%, ROC AUC 0.83) and DeEP-VERP (sens. 69%, spec. 74%, ROC AUC 0.76) maps. Proportional to total mapped area, the DeEP-400 map area was significantly smaller than DeEP-VERP map area (19.0 ± 7.6 % vs 26.4 ± 14.3%; p=0.02). Delivering the S2 at the conventional VERP + 20 ms using a 10 ms decrement definition yielded a sensitivity of 84.6% and a specificity of 62.0% with a target ablation area of 33.9 cm2. With the optimised protocol of delivering the S2 at 400 ms using a 20 ms decrement definition, the sensitivity remains high at 76.9% with an improved specificity of 79.0%, thus reducing the ablation target area by 50% to 16.8 cm2. 92% patients were free of any VT after DeEP-400 guided ablation at 6-month median follow-up. CONCLUSION: In this prospective, mechanistic study utilising omnipolar technology to explore a range of S2 extra-stimuli and decrement thresholds, DeEPs were optimally defined by a conduction delay of ≥ 20 ms with an S2 extra-stimulus coupling interval of 400 ms or VTCL to more accurately localise the VT exit site. This optimised DeEP mapping protocol further refines identification of the critical myocardial sites involved in the initiation and maintenance of VT. [Figure: see text] [Figure: see text] Oxford University Press 2023-05-24 /pmc/articles/PMC10207243/ http://dx.doi.org/10.1093/europace/euad122.313 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle 13.4.3 - Ablation of Ventricular Arrhythmias
Al-Sheikhli, J
Winter, J
Patchett, I
Lim, V G
Marshall, L
Orini, M
Williams, S
Osman, F
Lellouche, N
Roca Luque, I
Lambiase, P
Porta-Sanchez, A
Dhanjal, T
Optimisation of decrementing evoked potential mapping for functional substrate identification in ischaemic ventricular tachycardia ablation
title Optimisation of decrementing evoked potential mapping for functional substrate identification in ischaemic ventricular tachycardia ablation
title_full Optimisation of decrementing evoked potential mapping for functional substrate identification in ischaemic ventricular tachycardia ablation
title_fullStr Optimisation of decrementing evoked potential mapping for functional substrate identification in ischaemic ventricular tachycardia ablation
title_full_unstemmed Optimisation of decrementing evoked potential mapping for functional substrate identification in ischaemic ventricular tachycardia ablation
title_short Optimisation of decrementing evoked potential mapping for functional substrate identification in ischaemic ventricular tachycardia ablation
title_sort optimisation of decrementing evoked potential mapping for functional substrate identification in ischaemic ventricular tachycardia ablation
topic 13.4.3 - Ablation of Ventricular Arrhythmias
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207243/
http://dx.doi.org/10.1093/europace/euad122.313
work_keys_str_mv AT alsheikhlij optimisationofdecrementingevokedpotentialmappingforfunctionalsubstrateidentificationinischaemicventriculartachycardiaablation
AT winterj optimisationofdecrementingevokedpotentialmappingforfunctionalsubstrateidentificationinischaemicventriculartachycardiaablation
AT patchetti optimisationofdecrementingevokedpotentialmappingforfunctionalsubstrateidentificationinischaemicventriculartachycardiaablation
AT limvg optimisationofdecrementingevokedpotentialmappingforfunctionalsubstrateidentificationinischaemicventriculartachycardiaablation
AT marshalll optimisationofdecrementingevokedpotentialmappingforfunctionalsubstrateidentificationinischaemicventriculartachycardiaablation
AT orinim optimisationofdecrementingevokedpotentialmappingforfunctionalsubstrateidentificationinischaemicventriculartachycardiaablation
AT williamss optimisationofdecrementingevokedpotentialmappingforfunctionalsubstrateidentificationinischaemicventriculartachycardiaablation
AT osmanf optimisationofdecrementingevokedpotentialmappingforfunctionalsubstrateidentificationinischaemicventriculartachycardiaablation
AT lellouchen optimisationofdecrementingevokedpotentialmappingforfunctionalsubstrateidentificationinischaemicventriculartachycardiaablation
AT rocaluquei optimisationofdecrementingevokedpotentialmappingforfunctionalsubstrateidentificationinischaemicventriculartachycardiaablation
AT lambiasep optimisationofdecrementingevokedpotentialmappingforfunctionalsubstrateidentificationinischaemicventriculartachycardiaablation
AT portasancheza optimisationofdecrementingevokedpotentialmappingforfunctionalsubstrateidentificationinischaemicventriculartachycardiaablation
AT dhanjalt optimisationofdecrementingevokedpotentialmappingforfunctionalsubstrateidentificationinischaemicventriculartachycardiaablation